Search Result

Results for "

0.29

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Adenosine Receptor (1) Aminopeptidase (1) AMPK (3) Apoptosis (10) Autophagy (5) Bacterial (3) Bcl-2 Family (1) Beta-lactamase (1) Btk (1) Caspase (1) CDK (1) CFTR (1) CGRP Receptor (1) Checkpoint Kinase (Chk) (1) Cholinesterase (ChE) (4) ClpP (1) Dengue Virus (1) Dipeptidyl Peptidase (3) DNA/RNA Synthesis (2) EGFR (7) Endogenous Metabolite (2) Enterovirus (1) Epigenetic Reader Domain (3) ERK (1) Estrogen Receptor/ERR (3) Flavivirus (1) FLT3 (5) GABA Receptor (2) Glycosidase (1) HCV (1) HCV Protease (1) HDAC (5) Histone Methyltransferase (1) HIV Protease (1) HSV (1) IGF-1R (1) IKK (1) Influenza Virus (1) Integrin (2) Interleukin Related (3) IRE1 (1) Isotope-Labeled Compounds (6) JNK (3) Kallikrein (1) Keap1-Nrf2 (1) Macrophage migration inhibitory factor (MIF) (1) Melanocortin Receptor (2) mGluR (2) Microsomal Triglyceride Transfer Protein (MTP) (1) Microtubule/Tubulin (3) Monoamine Transporter (1) mTOR (1) Na+/K+ ATPase (3) nAChR (1) Necroptosis (1) Neprilysin (1) NF-κB (3) NOD-like Receptor (NLR) (4) p38 MAPK (2) Parasite (2) PD-1/PD-L1 (1) Phosphodiesterase (PDE) (1) Phosphoglycerate Dehydrogenase (PHGDH) (1) PI3K (2) PIKfyve (1) Potassium Channel (1) PPAR (1) Protease Activated Receptor (PAR) (1) Proton Pump (4) Pyroptosis (1) Reactive Oxygen Species (ROS) (2) Reference Standards (4) SARS-CoV (3) Ser/Thr Protease (1) SHP2 (1) Src (1) TAM Receptor (5) TGF-β Receptor (1) Thrombin (1) TNF Receptor (1) Toll-like Receptor (TLR) (2) Trk Receptor (1) TRP Channel (1) Tyrosinase (1) VEGFR (1) Virus Protease (1) YAP (1) γ-secretase (1)
By Research Areas:	Cancer (43) Cardiovascular Disease (10) Endocrinology (1) Infection (14) Inflammation/Immunology (12) Metabolic Disease (13) Neurological Disease (18)

By Targets:

5-HT Receptor (1)

Adenosine Receptor (1)

Aminopeptidase (1)

AMPK (3)

Apoptosis (10)

Autophagy (5)

Bacterial (3)

Bcl-2 Family (1)

Beta-lactamase (1)

Btk (1)

Caspase (1)

CDK (1)

CFTR (1)

CGRP Receptor (1)

Checkpoint Kinase (Chk) (1)

Cholinesterase (ChE) (4)

ClpP (1)

Dengue Virus (1)

Dipeptidyl Peptidase (3)

DNA/RNA Synthesis (2)

EGFR (7)

Endogenous Metabolite (2)

Enterovirus (1)

Epigenetic Reader Domain (3)

ERK (1)

Estrogen Receptor/ERR (3)

Flavivirus (1)

FLT3 (5)

GABA Receptor (2)

Glycosidase (1)

HCV (1)

HCV Protease (1)

HDAC (5)

Histone Methyltransferase (1)

HIV Protease (1)

HSV (1)

IGF-1R (1)

IKK (1)

Influenza Virus (1)

Integrin (2)

Interleukin Related (3)

IRE1 (1)

Isotope-Labeled Compounds (6)

JNK (3)

Kallikrein (1)

Keap1-Nrf2 (1)

Macrophage migration inhibitory factor (MIF) (1)

Melanocortin Receptor (2)

mGluR (2)

Microsomal Triglyceride Transfer Protein (MTP) (1)

Microtubule/Tubulin (3)

Monoamine Transporter (1)

mTOR (1)

Na+/K+ ATPase (3)

nAChR (1)

Necroptosis (1)

Neprilysin (1)

NF-κB (3)

NOD-like Receptor (NLR) (4)

p38 MAPK (2)

Parasite (2)

PD-1/PD-L1 (1)

Phosphodiesterase (PDE) (1)

Phosphoglycerate Dehydrogenase (PHGDH) (1)

PI3K (2)

PIKfyve (1)

Potassium Channel (1)

PPAR (1)

Protease Activated Receptor (PAR) (1)

Proton Pump (4)

Pyroptosis (1)

Reactive Oxygen Species (ROS) (2)

Reference Standards (4)

SARS-CoV (3)

Ser/Thr Protease (1)

SHP2 (1)

Src (1)

TAM Receptor (5)

TGF-β Receptor (1)

Thrombin (1)

TNF Receptor (1)

Toll-like Receptor (TLR) (2)

Trk Receptor (1)

TRP Channel (1)

Tyrosinase (1)

VEGFR (1)

Virus Protease (1)

YAP (1)

γ-secretase (1)

By Research Areas:

Cancer (43)

Cardiovascular Disease (10)

Endocrinology (1)

Infection (14)

Inflammation/Immunology (12)

Metabolic Disease (13)

Neurological Disease (18)

104

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

DC-SX029	PIKfyve NF-κB IKK	Inflammation/Immunology
DC-SX029 is a potent SNX10 protein-protein interaction (PPI) inhibitor with oral activity with an estimated K_D constant of ~0.935 μM by surface plasmon resonance (SPR). DC-SX029 blocks the SNX10-PIKfyve interaction, thereby decreased the TBK1/c-Rel signaling activation. DC-SX029 does not affect the protein level of SNX10. DC-SX029 has the potential for inflammatory bowel disease (IBD) research .

PZ-II-029	GABA Receptor	Neurological Disease
PZ-II-029 is a GABAA positive allosteric modulator that selectively binds with high affinity to α6β3γ2. PZ-II-029 shows anti-migraine effects .

ASTX029 5+ Cited Publications	ERK Apoptosis	Cancer
ASTX029 (Example 1) is a potent dual ERK1/2 inhibitor (IC₅₀: 2.7 nM). ASTX029 has anti-cancer activity .

Pruvonertinib YK-029A	EGFR	Cancer
YK-029A is an orally active inhibitor of mutant EGFR，targeting to both the T790M mutations (EGFR ^T790M) and exon 20 insertion of EGFR (EGFRex20ins). YK-029A exhibits significant antitumor activity，and results tumor regression in EGFRex20ins-driven PDX models .

Velnacrine maleate HP 029; Hydroxytacrine maleate	Cholinesterase (ChE)	Neurological Disease
Velnacrine maleate (HP 029) is an orally active cholinesterase inhibitor that can be used for the research of Alzheimer's disease .

TAK-029	Integrin	Cardiovascular Disease
TAK-029 is a potent GP IIb/IIIa antagonist. TAK-029 has potent antithrombotic effects with bleeding time (BT) prolongation in arterial thrombosis models. TAK-029 can be used for the research of various arterial thrombotic diseases .

Rs-029	Na+/K+ ATPase	Others
Rs-029 is an inhibitor Na+/K+ ATPase and an activator for Mg2+ ATPase. Rs-029 decreases the ATP level in red blood cells .

*UCCF-029* free base**	Endogenous Metabolite	Others
UCCF-029 Free base is a potent activator of the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel. UCCF-029 Free base exhibits enhanced activity through benzannulation of the flavone A-ring at the 7,8-position. UCCF-029 Free base serves as a structural guide for the development of more effective flavonoid analogues. UCCF-029 Free base demonstrates improved potency compared to apigenin in activating wild-type CFTR. UCCF-029 Free base also exhibits potential for activating the mutant CFTR (G551D-CFTR) though not as robustly as apigenin.

NCA029	ClpP Apoptosis	Cancer
NCA029 is a potent and selective homo sapiens caseinolytic protease P (HsClpP) activator with an EC₅₀ of 0.15 μM. NCA029 acts on HsClpP to activate an ATF3-dependent integrative stress response, leading to colon cancer cell death .

Sym029	TNF Receptor	Cancer
Sym029 is a human IgG monoclonal antibody (mAb) targeting TNFRSF5/CD40. Sym029 can be used in cancer research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .

Denibulin hydrochloride MN-029	Microtubule/Tubulin	Cancer
Denibulin (MN-029) hydrochloride is an anti-angiogenic agent with anticancer activity. It can cause rapid closure of blood vessels in solid tumors and lead to dose-dependent killing of tumor cells, effectively enhancing the antitumor effects of radiation and cisplatin chemotherapy .

Stamulumab 1 Publications Verification MYO-029	TGF-β Receptor	Metabolic Disease
Stamulumab (MYO-029) is a recombinant human IgG1λ antibody that binds to myostatin and neutralizes its activity by preventing binding to its endogenous high-affinity receptor ActRIIB. Stamulumab leads to muscle fiber hypertrophy and not hyperplasia in SCID mice. Stamulumab has the potential for Becker muscular dystrophy (BMD), facioscapulohumeral dystrophy (FSHD), and limb-girdle muscular dystrophy (LGMD) research .

Velnacrine HP 029 free base; Hydroxytacrine	Cholinesterase (ChE)	Neurological Disease
Velnacrine (HP 029 free base) is an inhibitor for acetylcholinesterase (AChE), with an IC₅₀ of 3.27 μM. Velnacrine reverses the Scopolamine (HY-N0296)-induced amnesia in rat models, and exhibits acute toxicity with LD₅₀ of 65 mg/kg .

Aldometanib 5+ Cited Publications LXY-05-029	AMPK	Metabolic Disease
Aldometanib (LXY-05-029) is an orally active aldolase inhibitor. Aldometanib can activate lysosomal adenosine monophosphate-activated protein kinase (AMPK) and decreases blood glucose. Aldometanib can be used for the research of metabolic homeostasis .

Necrosis inhibitor 3	Necroptosis	Cancer
Necrosis inhibitor 3 (compound B3) is a poteng inhibitor of necrosis, with the IC₅₀ value of 0.29 nM in HT29 cells .

Antileishmanial agent-2	Parasite	Infection
Antileishmanial agent-2 shows submicromolar antileishmanial activity (IC₅₀ = 0.29 μM) and a very high selectivity index with respect to mammalian cells.

Gilteritinib hemifumarate 35+ Cited Publications ASP2215 hemifumarate	FLT3 TAM Receptor	Cancer
Gilteritinib (ASP2215) hemifumarate is a potent and ATP-competitive FLT3/AXL inhibitor with IC₅₀ of 0.29 nM/0.73 nM, respectively.

Gilteritinib 35+ Cited Publications ASP2215	FLT3 TAM Receptor	Cancer
Gilteritinib (ASP2215) is a potent and ATP-competitive FLT3/AXL inhibitor with IC₅₀s of 0.29 nM/0.73 nM, respectively.

RO5464466	Influenza Virus	Infection
RO5464466 is an hemagglutinin (HA) inhibitor of influenza H1N1 viruses. RO5464466 inhibits HA-mediated hemolysis of chicken erythrocytes with the IC₅₀ of 0.29 μM .

Neolitsine (+)-Neolitsine	Others	Cardiovascular Disease
Neolitsine ((+)-Neolitsine) is a vasodilator. Neolitsine can be isolated from the herb Cassytha filiformis. Neolitsine exhibits significant vasodilatory effects on precontracted rat aortic preparations with an IC₅₀ of 0.29 μM .

Adenosine receptor antagonist 1	Adenosine Receptor	Cancer
Adenosine receptor antagonist 1 is a A2aR-selective antagonist with an IC₅₀ of 0.29 nM and displays 14-fold more selective for A2aR than A2bR.

Mcl1-IN-12	Bcl-2 Family	Cancer
Mcl1-IN-12 (Compound F) is a selective Mcl-1 inhibitor, less potent at Bcl-2, with K_is of 0.29 and 3.1 μM, respectively. Anti-tumor activity .

Tubulin polymerization-IN-63	Microtubule/Tubulin	Cancer
Tubulin polymerization-IN-63 (compound 6) is a tubulin polymerization inhibitor. The IC₅₀ value of Tubulin polymerization-IN-63 for MES-SA cells is 0.29 μM. Tubulin polymerization-IN-63 can be used in cancer research .

S-N6-Methyladenosylhomocysteine	Histone Methyltransferase	Cancer
S-N6-Methyladenosylhomocysteine (Chart 1-1) is a potent inhibitor of histone methyltransferase DOT1L, with the IC₅₀ of 0.29 μM. S-N6-Methyladenosylhomocysteine plays an important role in cancer research .

FR-171113	Protease Activated Receptor (PAR)	Cardiovascular Disease
FR171113 is a specific and non-peptide thrombin receptor antagonist. FR171113 exhibits the antithrombotic effects of a PAR1 antagonist. FR171113 inhibits thrombin-induced platelet aggregation with an IC₅₀ of 0.29 μM. .

HS024	Melanocortin Receptor	Metabolic Disease
HS024 is a selective MC4 receptor antagonist, with K_is of 0.29, 3.29, 5.45, and 18.6 nM for MC4, MC5, MC3, and MC1, respectively. HS024 increase food intake .

HS024 TFA	Melanocortin Receptor	Metabolic Disease
HS024 is a selective MC4 receptor antagonist, with K_is of 0.29, 3.29, 5.45, 18.6 nM for MC4, MC5, MC3, and MC1, respectively. HS024 increase food intake .

TEAD-IN-9	YAP	Cancer
TEAD-IN-9 (compound 17) is a TEAD1 inhibitor with an IC₅₀ of 0.29 μM. TEAD-IN-9 targets the palmitoyl pocket of TEAD, thereby effectively inhibiting the binding of YAP-TEAD and blocking the transcriptional function of YAP-TEAD .

Hydrodolasetron	5-HT Receptor nAChR	Neurological Disease Cancer
Hydrodolasetron is a metabolite of Dolasetron (HY-B0750). Hydrodolasetron is more potent than Dolasetron in inhibiting nAChR. Hydrodolasetron is a 5-HT(3A)R blocker with an IC₅₀ of 0.29 nM. Hydrodolasetron has antiemetic activity .

Gilteritinib (Standard) ASP2215 (Standard)	Reference Standards FLT3 TAM Receptor	Cancer
Gilteritinib (Standard) is the analytical standard of Gilteritinib. This product is intended for research and analytical applications. Gilteritinib (ASP2215) is a potent and ATP-competitive FLT3/AXL inhibitor with IC₅₀s of 0.29 nM/0.73 nM, respectively.

(R)-Elexacaftor (R)-VX-445	CFTR	Inflammation/Immunology
(R)-Elexacaftor is an enantiomer of Elexacaftor (HY-111772). (R)-Elexacaftor is the Compound 37 from patent WO2018107100A1. (R)-Elexacaftor is a modulator of cystic fibrosis transmembrane conductance regulator (CFTR), the EC50 for CFTR dF508 is 0.29 uM .

ML267	Bacterial	Infection
ML267 a potent Sfp phosphopantetheinyl transferase (PPTases) inhibitor with an IC₅₀ of 0.29 μM. ML267 also inhibits AcpS-PPTase with an IC₅₀ of 8.1 μM. ML267 possesses specific Gram-positive-targeted bactericidal activities .

SDUY817	Neprilysin Aminopeptidase	Neurological Disease
SDUY817 is a dual APN/NEP inhibitor, with IC₅₀ values of 0.29 μM for APN and 7.4 μM for NEP. SDUY817 exerts analgesic effects in a concentration- and time-dependent manner, and can be used for research in the field of neuropathic pain disorders .

Gilteritinib hemifumarate (Standard)	FLT3 TAM Receptor	Cancer
Gilteritinib hemifumarate (Standard) is the analytical standard of Gilteritinib hemifumarate. This product is intended for research and analytical applications. Gilteritinib (ASP2215) hemifumarate is a potent and ATP-competitive FLT3/AXL inhibitor with IC50 of 0.29 nM/0.73 nM, respectively.

mTOR inhibitor-13	mTOR PI3K	Cancer
mTOR inhibitor-13 (compound 9g), an aryl ureido compound, is a potent and selective mTOR inhibitor with an IC₅₀ of 0.29 nM. mTOR inhibitor-13 also inhibits PI3K-α with an IC₅₀ of 119 nM .

Metallo-β-lactamase-IN-15	Beta-lactamase	Infection
Metallo-β-lactamase-IN-15 (Compound ±13) is a potent MBL inhibitor, the IC₅₀ values for NDM-1、IMP-1 and VIM-2 were 0.29 μM, 0.088 μM and 0.063 μM, respectively .

L-AP4 monohydrate L-APB monohydrate	mGluR	Neurological Disease
L-AP4 (L-APB) monohydrate is a potent and specific agonist for the group III mGluRs, with EC₅₀s of 0.13, 0.29, 1.0, 249 μM for mGlu₄, mGlu₈, mGlu₆ and mGlu₇ receptors, respectively .

L-AP4 1 Publications Verification L-APB	mGluR	Neurological Disease
L-AP4 (L-APB) is a potent and specific agonist for the group III mGluRs, with EC₅₀s of 0.13, 0.29, 1.0, 249 μM for mGlu₄, mGlu₈, mGlu₆ and mGlu₇ receptors, respectively .

CI-1044 PD-189659	Phosphodiesterase (PDE)	Inflammation/Immunology
CI-1044 is an orally active PDE4 inhibitor with IC₅₀s of 0.29, 0.08, 0.56, 0.09 μM for PDE4A5, PDE4B2, PDE4C2 and PDE4D3, respectively.

IQ-3 2 Publications Verification	JNK	Inflammation/Immunology
IQ-3 is a specific inhibitor of the c-Jun N-terminal kinase (JNK) family, with preference for JNK3. IQ-3 exhibits K_d values of 0.24 μM, 0.29 μM and 0.066 μM for JNK1, JNK2 and JNK3, respectively .

VEGFR-IN-3	VEGFR Apoptosis	Cancer
VEGFR-IN-3 (compound 3f) is a VEGFR inhibitor. VEGFR-IN-3 inhibits OVCAR-4 and MDA-MB-468 cancer cells growth with IC₅₀s of 0.29 and 0.35 μM, respectively. VEGFR-IN-3 can be used for the research of cancer .

Fulvestrant Maximum Cited Publications 103 Publications Verification ICI 182780; ZD 9238; ZM 182780	Estrogen Receptor/ERR Autophagy Apoptosis	Cancer
Fulvestrant (ICI 182780) is a pure antiestrogen and a potent estrogen receptor (ER) antagonist with an IC₅₀ of 9.4 nM. Fulvestrant is also a GPR30 agonist. Fulvestrant effectively inhibits the growth of ER-positive MCF-7 cells with an IC₅₀ of 0.29 nM. Fulvestrant also induces autophagy and has antitumor efficacy .

SDUY038	SHP2	Cancer
SDUY038 is a SHP2 allosteric inhibitor, with an IC₅₀ of 1.2 μM and K_D of 0.29 μM, respectively. SDUY038 exhibits pan-antitumor activity (IC₅₀ = 7-24 μM) by suppressing pERK expression. SDUY038 exhibits t_1/2 of 3.95 h by oral administration .

PHGDH-IN-5	Phosphoglycerate Dehydrogenase (PHGDH)	Cancer
PHGDH-IN-5 (Compound B12) is a covalen inhibitor of PHGDH with an IC₅₀ value of 0.29 μM. PHGDH-IN-5 can inhibit cell proliferation in cancer cell lines overexpressing PHGDH. PHGDH-IN-5 can reduce the production of serine derived from glucose in MDA-MB-468 cells .

CDK2-IN-23	CDK	Cancer
CDK2-IN-23 (Compound 17) is a kinase selective and highly potent CDK2 inhibitor (IC₅₀ = 0.29 nM). CDK2-IN-23 shows the pharmacodynamic inhibition of CDK2 in CCNE1-amplified mouse models. CDK2-IN-23 can be used for the research of cancer .

Cat. No.	Product Name

HY-L029

Autophagy Compound Library

1,663 compounds

Autophagy is a lysosomal degradation pathway that is essential for cell survival, differentiation, development, and homeostasis. The process of autophagy in mammalian cells is as follows: a portion of cytoplasm, including organelles, is enclosed by a phagophore or isolation membrane to form an autophagosome. The outer membrane of the autophagosome subsequently fuses with the endosome and then the lysosome, and the internal material is degraded. Autophagy plays a wide variety of physiological and pathophysiological roles. Defective autophagy contributes to various pathologies, including infections, cancer, neurodegeneration, aging, and heart disease.

MCE provides a unique collection of 1,663 autophagy pathway-related compounds that is a useful tool for the research of autophagy-related regulation and diseases.

Cat. No.	Product Name	Target	Research Area

HY-P1215A

HS024 TFA	Melanocortin Receptor	Metabolic Disease
HS024 is a selective MC4 receptor antagonist, with K_is of 0.29, 3.29, 5.45, 18.6 nM for MC4, MC5, MC3, and MC1, respectively. HS024 increase food intake .

HY-P1215

HS024	Melanocortin Receptor	Metabolic Disease
HS024 is a selective MC4 receptor antagonist, with K_is of 0.29, 3.29, 5.45, and 18.6 nM for MC4, MC5, MC3, and MC1, respectively. HS024 increase food intake .

Cat. No.	Product Name	Target	Research Area

HY-P99588

Stamulumab 1 Publications Verification MYO-029	TGF-β Receptor	Metabolic Disease
Stamulumab (MYO-029) is a recombinant human IgG1λ antibody that binds to myostatin and neutralizes its activity by preventing binding to its endogenous high-affinity receptor ActRIIB. Stamulumab leads to muscle fiber hypertrophy and not hyperplasia in SCID mice. Stamulumab has the potential for Becker muscular dystrophy (BMD), facioscapulohumeral dystrophy (FSHD), and limb-girdle muscular dystrophy (LGMD) research .

HY-P991460

Sym029	TNF Receptor	Cancer
Sym029 is a human IgG monoclonal antibody (mAb) targeting TNFRSF5/CD40. Sym029 can be used in cancer research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .

Species:	Human (3)
Tag:	His (1) GST (1) Fc (1)
Source:	HEK293 (2) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source

HY-P71471

	HADHB Protein, Human (GST) 3-ketoacyl-CoA thiolase; Acetyl CoA acyltransferase; Acetyl-CoA acyltransferase; Beta ketothiolase; Beta-ketothiolase; ECHB; ECHB_HUMAN; HADH; Hadhb; beta subunit; Hydroxyacyl Coenzyme A (CoA) dehydrogenase beta subunit; MGC87480; MSTP 029; MSTP029; MTPB; TP beta; TP-beta; TPbeta; Trifunctional enzyme subunit beta; Trifunct	Human	E. coli
	HADHB protein is an important component of mitochondrial trifunctional enzymes and directs three decisive reactions in the mitochondrial β-oxidation pathway. This pathway is critical for generating energy across tissues, breaking down long-chain fatty acids into acetyl-CoA. HADHB Protein, Human (GST) is the recombinant human-derived HADHB protein, expressed by E. coli , with N-GST labeled tag.

HY-P76117

	TSPAN8 Protein, Human (HEK293, His) Tetraspanin-8; Tspan-8; CO-029; TSPAN8; TM4SF3	Human	HEK293
	TSPAN8 is a cell surface glycoprotein that is complexed with integrins and belongs to the four-span protein family. It has four hydrophobic domains. TSPAN8 mediates extracellular signal transduction processes and regulates cell development, activation, growth, and movement. In addition, TSPAN8 is expressed in different cancers and has potential roles in cancer prognosis and targeted therapy. TSPAN8 Protein, Human (HEK293, His) is the recombinant human-derived TSPAN8 protein, expressed by HEK293 , with N-6*His labeled tag.

HY-P76118

	TSPAN8 Protein, Human (HEK293, Fc) Tetraspanin-8; Tspan-8; CO-029; TSPAN8; TM4SF3	Human	HEK293
	TSPAN8 is a cell surface glycoprotein that is complexed with integrins and belongs to the four-span protein family. It has four hydrophobic domains. TSPAN8 mediates extracellular signal transduction processes and regulates cell development, activation, growth, and movement. In addition, TSPAN8 is expressed in different cancers and has potential roles in cancer prognosis and targeted therapy. TSPAN8 Protein, Human (HEK293, Fc) is the recombinant human-derived TSPAN8 protein, expressed by HEK293 , with N-mFc labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-12432S1

Gilteritinib-d8
Gilteritinib-d₈ is deuterium labeled Gilteritinib. Gilteritinib (ASP2215) is a potent and ATP-competitive FLT3/AXL inhibitor with IC50s of 0.29 nM/0.73 nM, respectively.

HY-13636S

Fulvestrant-d3
Fulvestrant-d₃ is the deuterium labeled Fulvestrant. Fulvestrant (ICI 182780) is a pure antiestrogen and a potent estrogen receptor (ER) antagonist with an IC₅₀ of 9.4 nM. Fulvestrant is also a GPR30 agonist. Fulvestrant effectively inhibits the growth of ER-positive MCF-7 cells with an IC₅₀ of 0.29 nM. Fulvestrant also induces autophagy and has antitumor efficacy .

HY-127165S2

Velnacrine-d4 hydrochloride
Velnacrine-d₄ (hydrochloride) is deuterium labeled Velnacrine.

HY-14806S2

Teneligliptin-d5

Teneligliptin-d₅ (MP-513-d₅) is deuterium labeled Teneligliptin. Teneligliptin (MP-513) hydrobromide hydrate is an orally active and selective dipeptidyl peptidase 4 (DPP-4) inhibitor (IC₅₀s: 0.37 and 0.29 nM for the human and rat DPP-4, respectively). Teneligliptin hydrobromide hydrate improves blood glucose levels and can be used in researches related to type 2 diabetes mellitus .

HY-127165S1

Velnacrine-d3 maleate
Velnacrine-d₃ (maleate) is the deuterium labeled Velnacrine maleate .

HY-127165S

Velnacrine-d3
Velnacrine-d₃ is the deuterium labeled Velnacrine .

HY-127165S3

Velnacrine-d4
Velnacrine-d₄ is deuterium labeled Velnacrine.

HY-17623S

Tegoprazan-d6

Tegoprazan (CJ-12420; RQ-00000004), a potassium-competitive acid blocker, is a reversible, oral active and highly selective inhibitor of gastric H+/K+-ATPase that could control gastric acid secretion and motility, with IC₅₀ values ranging from 0.29-0.52 μM for porcine, canine, and human H ⁺/K ⁺-ATPases in vitro. Tegoprazan significantly improves colitis in mice and enhances the intestinal epithelial barrier function. Tegoprazan is promising for research of Inflammatory bowel, gastric acid-related, motilityimpaired diseases .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P80923

	Trk B Antibody (YA029) TRKB	WB	Rat
	Trk B Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 92 kDa, targeting to Trk B. It can be used for WB assays with tag free, in the background of Rat.

HY-P81413

	ARID1A Antibody (YA1158) ARID1A; BAF250; C1orf4; ELD; HOSA1; Osa homolog 1; OSA1 nuclear protein; SMARCF1; MRD14; p270; B120; BM029	IHC-P	Human
	ARID1A Antibody (YA1158) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1158), targeting ARID1A. ARID1A Antibody (YA1158) can be used for IHC-P experiment in human background.

HY-P84152

	TSPAN8 Antibody (YA3849) CO-029; TM4SF3	WB, IHC-P, FC, ELISA	Human
	TSPAN8 Antibody (YA3849) is a mouse-derived and non-conjugated IgG1 antibody, targeting to TSPAN8. It can be applicated for WB, IHC-P, FC, ELISA assays, in the background of human.